V

ertex Pharmaceuticals on Wednesday selected two cystic fibrosis drugs to advance into late-stage clinical trials as part of different triple-combination regimens. The decision was based on new clinical data, also disclosed Wednesday, showing large improvements in lung function for patients with a type of cystic fibrosis that is genetically resistant to all treatments now on the market.

If the two new drugs reach the market, Vertex would be able to successfully treat the underlying cause of cystic fibrosis in roughly 90 percent of the 75,000 patients worldwide, up from roughly half.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.